Pfizer sets sights on R&D strategy amid modest FY25 results [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
In FY25, Pfizer generated full-year revenues of $62.6bn. While this meets the company's previously adjusted FY25 profit forecast of $62bn, it represents a 2% operational decline compared to FY24. Earnings per share (EPS) were in line with Citi analyst consensus, standing at $1.36, although they were lower than the 2024 rate of $1.41. The company also reaffirmed its 2026 financial guidance, with revenues between $59.5bn and $62.5bn expected, with a diluted EPS range of $2.80 to $3.00. The results follow a tough 2025 for Pfizer, in which the company has battled with declining Covid-19 vaccine sales and the upcoming loss of exclusivity impacting several key drugs in its portfolio, including Janus kinase (JAK) inhibitor, Xeljanz (tofacitinib). Currently, Pfizer forecasts that patent expiries will result in $1.5bn of revenue losses in FY26. Despite this overall loss, 2025 revenues were looking more favourable when Covid-19 vaccines Paxlovid (nirmatrelvir/ritonavir) and Comirnaty (Co
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Is Sanofi (ENXTPA:SAN) Offering Value After Recent Share Price Weakness [Yahoo! Finance]Yahoo! Finance
- Why OpenAI's drug royalties deal won't work [Yahoo! Finance]Yahoo! Finance
- GSK Advances Respiratory And Vaccine Growth With Key RSV And Asthma Moves [Yahoo! Finance]Yahoo! Finance
- Latent TB Diagnostics Research Report 2026: Global Market Analysis and Forecasts 2025-2029 by Assay, Risk Factor, and Lab/Place with Executive and Consultant Guides [Yahoo! Finance]Yahoo! Finance
- Is Sanofi SA (SNY) One of the Best Cheap Stocks to Buy for 2026 [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 2/6/26 - Form 6-K
- 2/5/26 - Form S-8
- 1/29/26 - Form 6-K
- SNY's page on the SEC website